Condition: Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms · Sponsor: Xintian Pharmaceutical
Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules. Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study. Interventions: Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks. Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.
This description comes directly from the study's public registry record.
Peiling Shi · +8619821240029 · lc-spl@xtyyoa.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Tongren Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Peking University Shenzhen Hospital | Shenzhen, Guangdong, China | Not Yet Recruiting |
| The Central Hospital Of WUHAN | Wuhan, Hubei, China | Not Yet Recruiting |
| Wuhan No.1 Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Not Yet Recruiting |
| Wuxi No.2 People's Hospital | Wuxi, Jiangsu, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05551221